Bacterial vaginosis affects up to 30% of women worldwide, leading to discomfort and a higher risk of reproductive and infectious complications. Unfortunately, current treatments often fall short, with a high rate of recurrence. That’s where BNT331 comes in: a cutting-edge therapy targeting the root cause of BV with the potential to offer a more effective and resilient solution.

We’re excited to introduce the BNT331-01 trial, a pioneering Phase I study aimed at transforming the treatment of bacterial vaginosis (BV). This randomized, double-blind, placebo-controlled trial is designed to explore the safety, tolerability, and pharmacokinetics of BNT331, a novel treatment administered in single ascending doses to healthy women and multiple ascending doses to those diagnosed with BV.

Targeted Action: BNT331 selectively combats Gardnerella spp., a primary culprit behind BV, without harming beneficial bacteria.

Innovative Approach: Leveraging a modified phage-derived endolysin, BNT331 aims to break through the biofilm barrier that shields harmful bacteria, a challenge that traditional antibiotics struggle to overcome.

Hope for Recurrent Sufferers: Especially designed for those suffering from recurrent or persistent BV, BNT331 represents a beacon of hope where other treatments may not have succeeded.

We’re looking for women to join us on this journey! Check if you meet the criteria below:

Inclusion Criteria:

• Healthy women (for single ascending dose study)
• Women diagnosed with bacterial vaginosis (for multiple ascending dose study)
• Non-pregnant, non-breastfeeding, and pre-menopausal individuals

Exclusion Criteria:

• Known hypersensitivity to antibiotics
• Participation in another clinical trial within the last 30 days
• Any condition that, in the investigator’s opinion, could compromise the study’s integrity or participant’s safety